Agios Pharmaceuticals Company Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.

Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.

Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Agios Pharmaceuticals, Inc.

Country	United States
Founded	2007
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	386
CEO	Brian Goff

Contact Details

Address: 88 Sidney Street Cambridge, Delaware 02139 United States
Phone	617 649 8600
Website	agios.com

Stock Details

Ticker Symbol	0HB0
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US00847X1046
SIC Code	2836

Key Executives

Name	Position
Brian Goff	Chief Executive Officer
Cecilia Jones	Chief Financial Officer
Christopher J. Taylor	Head of Investor Relations